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Objectives. This prospective, randomized, double-blind multi-
center trial evaluated the efficacy and safety of a single bolus
injection of the novel modified tissue-type plasminogen activator
(t-PA) E6010 in the treatment of acute myocardial infarction
compared with that of native t-PA.
Background. E6010 is a novel modified t-PA with a prolonged
half-life (t1/2 alpha >223 min) compared with native t-PA (t1/2
alpha 5 4 min). E6010 can be administered in patients as a single
intravenous bolus injection, and early recanalization can be
expected.
Methods. The efficacy of E6010 was compared with that of
native t-PA in 199 patients with acute myocardial infarction who
were treated within 6 h of onset in a prospective, randomized,
double-blind multicenter trial. Patients were given either
0.22 mg/kg body weight of E6010 intravenously over 2 min or
native t-PA (tisokinase) 28.8 mg or 14.4 million IU (10% of the
total dose over 1 to 2 min, the remainder infused over 60 min).
Results. The primary end point was the recanalization rate of
the infarct-related coronary artery at 60 min after the start of
treatment. Time to reperfusion was shorter in the E6010 group
than in the native t-PA group. Thrombolysis in Myocardial
Infarction flow grade 2 or 3 recanalization at 15, 30, 45 and 60 min
after administration was observed in 37%, 62%, 74% and 79%
(95% confidence interval [CI] 70% to 87%) of the E6010-treated
patients and in 14%, 32%, 50% and 65% (95% CI 55% to 74%) of
native t-PA-treated patients, respectively (p 5 0.032 at 60 min).
Conclusions. The present study indicates that, compared with
native t-PA, a single bolus injection of E6010 over 2 min produces
a higher rate of early recanalization of the infarct-related coro-
nary artery without fatal bleeding complications.
(J Am Coll Cardiol 1997;29:1447–53)
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The aim of thrombolytic therapy for acute myocardial infarc-
tion is rapid lysis of thrombi in the infarct-related coronary
artery to restore blood flow as early as possible. However, the
widely used thrombolytic agent native tissue-type plasminogen
activator (native t-PA) is administered by intravenous infusion
because of its short half-life. The angiographic substudy of the
Global Utilization of Streptokinase and TPA for Occluded
Coronary Arteries (GUSTO) trials (1) indicated that front-
loaded alteplase resulted in both a higher percentage of early
vessel patency and significantly better survival than streptoki-
nase. However, the front-loaded regimen followed by contin-
uous intravenous infusion is cumbersome.
In the novel modified t-PA E6010, cysteine 84 in the
epidermal growth factor domain has been replaced by serine,
resulting in a plasma half-life (t1/2 alpha $23 min) longer than
that of native t-PA (t1/2 alpha 5 4 min) (2,3). Because of its
longer half-life, E6010 can be administered intravenously as a
single bolus injection. In a preliminary study (4), we reported
that a single intravenous bolus injection of E6010 is effective in
achieving early recanalization and a high recanalization rate,
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and 0.22 mg/kg body weight of E6010 was established as the
optimal dose. In the present study, we conducted a prospective,
randomized, double-blind multicenter trial to examine the
efficacy and safety of E6010 comparison with that of native
t-PA in patients with acute myocardial infarction.
Methods
Patients. The patients provided informed consent, and the
protocol was approved by the institutional review board of
each of the 84 participating hospitals. Patients were enrolled
between May 1993 and January 1994. The inclusion criteria
were 1) treatment initiation within 6 h of onset of infarction; 2)
total occlusion of the infarct-related coronary artery proved by
coronary angiography after intracoronary administration of
nitrates (isosorbide dinitrate or nitroglycerin); and 3) weight
,100 kg and a negative skin test for allergy to the test drug.
Age was not a criterion, although patients #75 years old were
preferentially enrolled.
Patients were excluded if they satisfied any of the following
criteria: 1) bleeding diathesis or hemorrhage symptoms (gas-
trointestinal or urinary tract bleeding, retroperitoneal or intra-
cranial hemorrhage, hemoptysis, hemorrhagic diabetic reti-
nopathy or other hemorrhagic eye diseases); 2) head injury,
intracranial tumor, arteriovenous malformation or aneurysm;
3) history of cerebrovascular disease within the 6 months
before the trial; 4) severe, poorly controlled hypertension
(although no clear stipulations regarding blood pressure were
made, the consensus among the clinicians participating in
the study was that patients with systolic blood pressure
.200 mm Hg and diastolic blood pressure .120 mm Hg
should be excluded); 5) operation within 2 weeks of infarction;
6) severe complications, such as free ventricular wall rupture,
ventricular septal perforation, papillary muscle rupture, mul-
tiple organ failure or cardiogenic shock unresponsive to vaso-
pressor drugs; 7) prolonged cardiopulmonary resuscitation; 8)
suspected left atrial thrombus (mitral stenosis associated with
atrial fibrillation); 9) previous thrombolytic therapy for the
infarction to be treated; 10) myocardial infarction as a com-
plication of percutaneous transluminal coronary angioplasty;
11) history of hypersensitivity to vaccines or other biologic
preparations; 12) serious liver or renal disease; and 13) preg-
nancy or suspected pregnancy.
Study design and medications. All patients underwent
coronary angiography and administration of intracoronary
nitroglycerin before receiving the fibrinolytic agent. Patients
were then randomly assigned to receive either an intravenous
bolus injection of 0.22 mg/kg of E6010 over 2 min, followed by
infusion of native t-PA placebo dissolved in 100 ml of saline
over 60 min (10% of the total native t-PA placebo dose was
given as a bolus injection over 1 to 2 min; the remainder was
infused over 60 minutes), or an intravenous bolus injection of
E6010 placebo over 2 min, followed by infusion of 14.4 million
IU (28.8 mg) of native t-PA dissolved in 100 ml of saline over
60 min (10% of the total dose given as a bolus injection over 1
to 2 min; the remainder was infused over 60 min). The native
t-PA administration schedule conformed to the indications for
use currently used in Japan.
E6010 (Eisai Co., Ltd., Tokyo, Japan) was supplied as a
freeze-dried injectable preparation in vials containing 22 mg of
the drug. The specific activity of E6010 is ;125,000 IU/mg, and
it has a molecular weight of 68 kilodaltons. Native t-PA
(tisokinase, Asahikasei Kogyo Co., Ltd., Tokyo, Japan) was
also supplied as a freeze-dried preparation in vials for injection
containing 3.6 million IU (7.2 mg) of the drug. A total of
5,000 U of heparin was given intravenously immediately before
coronary angiography, during which intracoronary administra-
tion of a nitrate was used to demonstrate total occlusion of the
infarct-related coronary artery, a patient eligibility criterion.
End points. The primary end point was Thrombolysis in
Myocardial Infarction (TIMI) grade 2 or 3 recanalization of
the infarct-related coronary artery at 60 min of treatment
initiation; evaluation was performed according to the TIMI
classification (5): grade 0 5 no reperfusion; grade 1 5 throm-
bolysis without myocardial reperfusion; grade 2 5 partial
reperfusion; and grade 3 5 complete reperfusion. Secondary
end points included recanalization of the infarct-related artery
at 15, 30 and 45 min of treatment initiation and therapy-related
bleeding complications. Only patients with an angiographically
proved occlusion of the infarct-related artery were selected for
the study.
Fibrinolysis assays. Blood samples were collected in ci-
trate containing D-Phe-Pro-Arg-CH2CI (PPACK) 1 mmol/
liter (6). Blood samples were obtained just before and 60 and
120 min and 24 h after test drug administration and were then
centrifuged. All plasma samples were stored at 220°C until
analysis.
Plasminogen and alpha2-plasmin inhibitor activity were
assayed using the chromogenic substrate S-2251 test (7).
Fibrinogen levels were measured using the clotting rate
method (8); fibrinogen degradation product (D-dimer) levels
were measured by enzyme-linked immunosorbent assay (9).
Statistical analysis and sample size estimation. All analy-
ses were performed using the Statistical Analysis System (SAS
Institute, Ltd., Tokyo, Japan) program and an NEC PC-9821
AP computer. Results are expressed as mean value 6 SD.
Group differences in baseline characteristics were assessed by
the Student t and chi-square tests. Chi-square analysis was used
to analyze differences in recanalization, reocclusion rates and
bleeding complications. The subgroup effects of recanalization
were investigated using the Cochran-Mantel-Haenszel test. A
Wilcoxon signed rank test was used to assess changes in
fibrinolytic variables versus pretreatment values. All tests were
Abbreviations and Acronyms
CI 5 confidence interval
GUSTO 5 Global Utilization of Streptokinase and TPA for
Occluded Coronary Arteries
TIMI 5 Thrombolysis in Myocardial Infarction
t-PA 5 tissue-type plasminogen activator
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two-tailed and were performed at a level of significance of p ,
0.05.
The study was scheduled to be performed with 100 patients/
group. This sample size gave 80% power to detect a 20%
absolute difference in TIMI grade 2 or 3 recanalization at
60 min after treatment.
The primary objective of the trial was addressed using the
95% confidence interval (CI) for the difference in recanaliza-
tion at 60 min after treatment. As a secondary objective,
recanalization at 15, 30 and 45 min after treatment was also
studied using 95% CI. Difference of recanalization rate 60 min
after treatment in the two treatment groups was analyzed using
chi-square analysis with the Yates correction for continuity.
Results
Clinical characteristics. A total of 211 patients were en-
rolled, 104 of whom were randomly assigned to receive E6010
and 107 native t-PA. Seven patients in the E6010 group and
five in the native t-PA group were excluded from the analysis
because the patients were either found to meet the exclusion
criteria or the study protocol was not observed (i.e., in the
E6010 group, mitral stenosis associated with atrial fibrillation
in one patient, incomplete obstruction of the coronary artery
before drug administration in two, .6 h from onset of myo-
cardial infarction to initiation of administration in one, failure
to receive the nitrate agent before therapy in two and fibrino-
lytic agent administered within 60 min of completion of
intravenous infusion in one patient; in the native t-PA group,
incomplete obstruction of the coronary artery before drug
administration in two patients, saphenous vein bypass graft in
one, fibrinolytic agent administered within 60 min of comple-
tion of intravenous infusion in one and no coronary angiogra-
phy 60 min after start of intravenous infusion in one). As a
result, 97 patients in the E6010 group and 102 in the native
t-PA group provided evaluable angiograms.
Table 1 shows the baseline patient characteristics, which
were similar in the two treatment groups. There were no
significant differences between the two groups for any charac-
teristic. The mean length of time from symptom onset to
treatment initiation was also similar in the two groups. The
actual dose of E6010 administered was 13.7 6 2.4 mg and that
of native t-PA was 28.8 mg.
Recanalization rate. Figures 1 and 2 show recanalization
rates on the basis of coronary angiograms performed at 15-min
intervals from the start of test drug administration. TIMI flow
grade readings were made by interpreting the cine films in
blind manner with regards to the identity of the agent admin-
istered to the patients. Recanalization rates for TIMI flow
grade 2 or 3 and grade 3 alone in the E6010 and native t-PA
groups are shown in Figures 1 and 2, respectively. At 60 min,
the recanalization rates for TIMI flow grade 2 or 3, the primary
end point, and TIMI grade 3 were significantly higher in the
E6010 group than in the native t-PA group (p , 0.05). The
recanalization rate increased with time after treatment in both
groups, but E6010 produced a significantly higher recanaliza-
tion rate than native t-PA at each assessment time (p , 0.01),
the secondary end point, particularly at 15 and 30 min. The
rate of recanalization for TIMI flow grade 3 at 60 min after a
single bolus injection of 0.22 mg/kg of E6010 was 69% in a
previous dose-finding study (4). With the same regimen, the
rate of TIMI flow grade 2 or 3 recanalization was 78% at
60 min in the same study (4), consistent with the 79% observed
in the present study.
The rates of TIMI flow grade 2 or 3 recanalization and
TIMI grade 3 recanalization alone were significantly higher in
the E6010 group than in the native t-PA group regardless of
the infarct-related artery or the time from onset of symptoms
to treatment initiation (p , 0.05 by Cochran-Mantel-Haenszel
test).
Adjunct therapy. During the first 60 min after test drug
administration, use of other thrombolytic drugs, anticoagulant
agents (other than heparin) and antiplatelet agents was pro-
hibited. Only a total of 5,000 U of heparin was permitted
immediately before coronary angiography. Antithrombotic co-
therapy with aspirin, ticlopidine and argatroban was given
without changing the dose during the study at the discretion of
the attending physician, but there were no significant differ-
ences between the two groups in number of patients receiving
these drugs (Table 2). Antiarrhythmic agents, calcium antag-
onists, nitrates, analgesics or sedatives and antishock therapy
could be used freely.
At 60 min after test drug administration, additional throm-
bolytic therapy was permitted when judged necessary. Percu-
taneous transluminal coronary angioplasty and other types of
adjunct therapy were permitted at the discretion of the attend-
ing physician.
Bleeding complications. Bleeding complications, including
minor hemorrhage, occurred in eight E6010-treated and six
Table 1. Baseline Characteristics
E6010
Group
(n 5 97)
Native t-PA
Group
(n 5 102) p Value
Age (yr) 62 6 11 63 6 10 NS
Male (%) 81 76 NS
Body weight (kg) 62 6 11 61 6 10 NS
Previous MI (%) 7 12 NS
Time from symptom onset to
treatment initiation (h)
3.5 6 1.2 3.7 6 1.3 NS
Site of infarction (%)
Anterior 44 47 NS
Inferior 49 44 NS
Lateral 7 8 NS
Infarct-related artery (%)
RCA 43 42 NS
LAD 45 47 NS
LCx 11 11 NS
Data presented are mean value 6 SD or percent of patients. LAD 5 left
anterior descending coronary artery; LCx 5 left circumflex coronary artery;
MI 5 myocardial infarction; RCA 5 right coronary artery; t-PA 5 tissue-type
plasminogen activator.
1449JACC Vol. 29, No. 7 KAWAI ET AL.
June 1997:1447–53 SINGLE BOLUS INJECTION OF A MODIFIED t-PA IN AMI
native t-PA–treated patients (p 5 NS). Cerebral hemorrhage
occurred in one patient who received native t-PA, resulting in
death. One patient treated with E6010 experienced hemate-
mesis requiring blood transfusion.
Changes in plasma fibrinolytic variables. Thirty-four pa-
tients in the E6010 and 42 in the native t-PA group who
received no adjunct thrombolytic therapy were analyzed for
the effects of test drug treatment on plasma fibrinolysis. Table
3 shows the changes in fibrinolytic variables over time. De-
creases in plasminogen activity, alpha2-plasmin inhibitor activ-
ity and fibrinogen levels were observed after both E6010 and
native t-PA treatment. These variables returned to near-
baseline levels 24 h after drug administration.
Clinical outcome. Death within 7 days of treatment oc-
curred in four patients (4%) in the E6010 group and one (1%)
in the native t-PA group (p 5 NS). Adjunct therapies included
percutaneous transluminal coronary angioplasty and thrombo-
lytic therapy, which were used in 54 patients in the E6010
group and 62 in the native t-PA group (Table 2). No patient
underwent coronary artery bypass grafting. Among the pa-
tients receiving no adjunct therapy, reocclusion was seen in
four (9%) in the E6010 group and six (15%) in the native t-PA
group within 24 h and in five (13%) and seven (19%),
respectively, within 7 days. Among the patients who demon-
strated recanalization of TIMI flow grade 2 or 3 at 60 min after
treatment, reinfarction developed in two (3%) in the E6010
group and four (6%) in the native t-PA group within 24 h,
whereas four (5%) and seven (11%) patients, respectively,
showed evidence of reinfarction within 7 days. However, these
differences were not statistically significant.
Figure 1. Recanalization rate of infarct-related arter-
ies determined by coronary angiography at 15-min
intervals. Circles 5 TIMI flow grade 2 or 3, E6010
group; triangles 5 TIMI flow grade 2 or 3, native t-PA
group. 95% confidence intervals are shown in paren-
theses. p , 0.01, E6010 group versus native t-PA group
at 15, 30 and 45 min. p , 0.05, E6010 group versus
native t-PA group at 60 min.
Figure 2. Recanalization rate of infarct-related arter-
ies determined by coronary angiography at 15-min
intervals. Circles 5 TIMI flow grade 3, E6010 group;
triangles 5 TIMI flow grade 3, native t-PA group. 95%
confidence intervals are shown in parentheses. p ,
0.01, E6010 group versus native t-PA group at 15, 30
and 45 min. p , 0.05, E6010 group versus t-PA group
at 60 min.
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Discussion
Thrombolytic treatment. A number of recent reports (10–
12) have shown that early recanalization of the infarct-related
coronary artery significantly improves cardiac function and
reduces the mortality rate. Thus, rapid lysis of intracoronary
thrombi with thrombolytic agents is a particularly important
part of current treatment for acute myocardial infarction
(1,13,14).
Tisokinase, the control drug in the present study, is one of
two native t-PA preparations approved for clinical use in
Japan. The tisokinase dose (28.8 mg infused over 60 min, with
2.8 mg of this dose given as a bolus) seems low and the
evaluation of patency rate at 60 min unconventional compared
with studies of native t-PA performed in the United States and
Europe. However, this regimen of native t-PA (28.8 mg) (14.4
million IU, tisokinase) is currently a standard and extensively
used method in Japan for the treatment of acute myocardial
infarction, producing recanalization rates of 69% to 75% at
60 min, as reported in several Japanese studies (15,16). Plas-
minogen activating capacity is enhanced in the presence of
fibrin. The percentage of tisokinase binding to fibrin was 68%,
whereas that of alteplase was 66%; these values are practically
equivalent. Therefore, it is thought that the plasminogen
activating capacity of tisokinase is comparable to that of
alteplase (17). The administered dose of tisokinase adjusted
for body weight (assuming an average body weight of 60 kg for
Japanese patients) was 0.48 mg/kg, whereas that of alteplase
used in Japan is 0.5 mg/kg. In this regard, it is believed that the
dose equivalences of tisokinase and alteplase were ensured in
this study.
Comparison of the recanalization rate with higher doses,
including higher initial doses, of native t-PA and E6010 is
outside the scope of the present study. However, we would
not expect much increase in the recanalization rate at 60 min
with higher drug doses, without major bleeding complications
in the Japanese population, given the recanalization rates at
60 min achieved in the present study (;80% and 70% with
E6010 and native t-PA, respectively). The continuous intrave-
nous infusion required for native t-PA is cumbersome and
disadvantageous.
Pharmacokinetic considerations. The novel thrombolytic
agent E6010 is a modified t-PA with a longer biologic half-life
than that of native t-PA (2,3) and can thus be administered in
patients with acute myocardial infarction as a single intrave-
nous bolus injected over 2 min. Kinetic variables, area under
the curve derived from analyses of E6010 and native t-PA
Table 2. Adjunctive Therapy
Group
Antithrombotic
Cotherapy*
No Additional
Reperfusion
Therapy
Additional
Reperfusion
Therapy†
E6010 (n 5 97) 73 (75.3%) 43 (44.3%) 54 (55.7%)
Native t-PA
(n 5 102)
85 (83.3%) 40 (39.2%) 62 (60.8%)
*Aspirin, ticlopidine or argatroban. †Percutaneous transluminal coronary
angioplasty or thrombolytic agents, or both. Data presented are number (%) of
patients. t-PA 5 tissue-type plasminogen activator.
Table 3. Changes in Fibrinolytic Variables
Variable
Time of Measurement
Pre 60 min 120 min 24 h
Plasminogen activity (%)
E6010 group 81.8 6 17.6 48.8 6 14.5* 47.6 6 13.1* 65.7 6 14.2*
(n 5 34) (n 5 34) (n 5 34) (n 5 30)
Native t-PA group 83.7 6 19.9 67.9 6 19.9† 75.5 6 12.9† 82.5 6 15.9
(n 5 42) (n 5 41) (n 5 40) (n 5 40)
Alpha2PI activity (%)
E6010 group 76.4 6 19.9 21.9 6 14.6* 19.3 6 14.4* 52.4 6 19.9*
(n 5 32) (n 5 32) (n 5 32) (n 5 27)
Native t-PA group 79.5 6 19.9 49.3 6 21.7† 58.4 6 16.8† 68.9 6 28.1‡
(n 5 40) (n 5 39) (38) (38)
Fibrinogen level (mg/dl)
E6010 group 268.7 6 88.4 182.7 6 64.4* 170.2 6 66.0* 200.9 6 84.1§
(n 5 32) (n 5 32) (n 5 32) (n 5 27)
Native t-PA group 250.9 6 95.2 212.8 6 83.5\ 249.4 6 73.3 271.3 6 101.3
(n 5 42) (n 5 41) (n 5 39) (n 5 40)
D-dimer level (ng/ml)
E6010 group 227.8 6 178.7 832.1 6 686.6* 1707.8 6 1753.1* 950.1 6 875.4*
(n 5 34) (n 5 34) (n 5 34) (n 5 30)
Native t-PA group 210.7 6 223.6 582.7 6 451.8† 949.6 6 826.1† 672.3 6 723.0†
(n 5 42) (n 5 41) (n 5 40) (n 5 40)
*p , 0.001 and §p , 0.01 versus pretreatment (Pre) values for E6010 group. †p , 0.001, ‡p , 0.01 and \p , 0.05
versus pretreatment values for native tissue-type plasminogen activator (t-PA) by Wilcoxon signed rank test. Intergroup
comparisons by the Student t test showed that decreases in all variables, except for the D-dimer level at 60 and 120 min
and 24 h, were significantly greater in the E6010 group than in the native t-PA group (p , 0.05). Data presented are mean
value 6 SD. Alpha2PI 5 alpha2-plasmin inhibitor.
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antigens in plasma multiplied by the specific activity of each
t-PA, representing total thrombolytic activity during the first
60 min after drug administration, obtained in Phase I studies in
healthy volunteers (2), revealed that a single bolus injection of
13.2 mg (73,507 IUzmin per ml) of E6010 (assuming the
average body weight of Japanese patients to be 60 kg) was
comparable to a continuous infusion of 28.8 mg (70,050 IUzmin
per ml) of native t-PA over 60 min (3). In a previous
dose-finding study (4), E6010 administered as an intravenous
bolus over 2 min in patients with an acute myocardial infarc-
tion was shown to have an optimal dose of 0.22 mg/kg on the
basis of efficacy and safety.
Studies in an animal model of thrombosis have shown (18)
that E6010 given as an intravenous bolus has excellent throm-
bolytic effects. In a canine model (19) in which coronary artery
thrombi were induced using copper coils, intracoronary infu-
sion of similar doses of E6010 and native t-PA showed that
E6010 has more potent thrombolytic activity than native t-PA,
as demonstrated by decreased time to reperfusion, increased
reperfusion rate 60 min after treatment and decreased reoc-
clusion rate 60 min after reperfusion (19). Thus, the superiority
of E6010 is due to its formulation (i.e., a long plasma half-life
that enables bolus administration), resulting in high effective
plasma concentrations and, thus, a superior thrombolytic ef-
fect.
Recanalization rate. In the present study, coronary angiog-
raphy was performed every 15 min to confirm whether early
recanalization could be achieved. Although it is possible that
the frequent infusion of contrast agent may have had some
mechanical effect, the same procedures were performed in
each group, providing valid comparative data. The percent of
patients with TIMI flow grade 2 or 3 and flow grade 3 alone at
each assessment and the recanalization rate 60 min after
treatment were significantly better in patients treated with
0.22 mg/kg of E6010 as a 2-min bolus injection than that in
patients treated with 28.8 mg (14.4 million IU) of native t-PA
(p , 0.05). These findings indicate that E6010 produces an
immediate improvement in coronary blood flow in the majority
of patients. Recanalization at 60 min was used as the primary
end point because the results of a preliminary dose-finding
study (4) showed that TIMI flow grade 2 or 3 recanalization
60 min after drug administration was achieved in ;80% of
patients using a single bolus of 0.22 mg/kg of E6010, and
therefore there was no reason to expect an increase in the
recanalization rate after an additional 30 min. Furthermore, it
would have been unethical to wait an additional 30 min before
starting adjunctive therapy that might have been beneficial to
those patients in whom E6010 had not achieved coronary
artery patency at 60 min. Moreover, the total thrombolytic
activities of E6010 and native t-PA, represented by the kinetic
variables, were maintained at similar levels for the 60 min after
drug administration was initiated. Plasma native t-PA levels
decrease rapidly immediately after discontinuation of admin-
istration. In the GUSTO Angiographic Study (1), patency was
also evaluated at the completion of drug infusion.
Reteplase, which is a modified t-PA like E6010, has also
achieved good patency rates: 77.6% and 85.2% at 60 and
90 min after administration, respectively (20). The patency rate
at 60 min after administration (77.6%) is comparable to that of
E6010 (79.0%). However, the plasma half-life of reteplase is
shorter than that of E6010, and reteplase therefore requires
double-bolus administration, with administration of a second
bolus 30 min after the first bolus, whereas E6010 requires only
single-bolus administration. E6010 is therefore advantageous
in terms of convenience.
Bleeding complications. Bolus E6010 administration did
not cause the occurrence of bleeding complications at signifi-
cantly higher rates than those in the native t-PA group.
Fibrinolytic variables. The decreases in plasminogen activ-
ity, alpha2-plasmin inhibitor activity and fibrinogen levels at 60
and 120 min and 24 h after treatment initiation were signifi-
cantly greater in the E6010 group than in the native t-PA group
(p , 0.05), probably because 1) giving E6010 as a bolus over
2 min causes the plasma drug level to increase soon after
administration, and 2) E6010 has a lower affinity for fibrin than
native t-PA. We suggest that a state of increased thrombolysis
was maintained for a longer time in the E6010 group than in
the native t-PA group because of the longer biologic half-life of
E6010.
Reocclusion. The study protocol did not specify the adjunct
therapy to be used. Therefore it would not be appropriate to
compare the reocclusion rates in the E6010 and native t-PA
groups. However, the reocclusion rate in the E6010 group
within 7 days of treatment was similar to that observed for
native t-PA in previous studies (21).
To prevent early reocclusion after thrombolytic therapy,
heparin infusion and antiplatelet agents (including aspirin)
were used. Because some patients who experienced reocclu-
sion in this study were given these agents, the protective effect
against reocclusion of such drugs may not necessarily be
satisfactory. However, effective prevention of reocclusion using
native t-PA combined with urokinase or streptokinase has
been reported (22,23). Further study of the effect of adjunct
therapy on reocclusion prevention is needed.
Conclusions. From the results presented here, we conclude
that E6010, which can be administered as a single intravenous
bolus injection over 2 min, produces a higher rate of early
recanalization of infarct-related coronary arteries at 60 min
than native t-PA, which is administered as a continuous
intravenous infusion with an initial bolus injection of 10% of
the total dose. This finding is important because it is crucial in
clinical practice to achieve coronary artery patency within the
“golden hours” in the treatment of acute myocardial infarc-
tion.
Appendix
Participating Investigators and Institutions for the
E6010 Study Group
M. Nobuyoshi, Kokura Memorial Hospital; S. Suzuki, Sakakibara Heart
Institute; H. Sato, Hiroshima City Hospital; M. Sugiyama, Yokohama City
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University Urahune Hospital; T. Sone, Ogaki Municipal Hospital; F. Takatsu,
Anjo Kosei Hospital; Y. Hiasa, Komatushima Red Cross Hospital; M. Kijima,
Hoshi General Hospital; T. Motomiya, Tokyo Metropolitan Hiroo General
Hospital; N. Nakamura, Matsue Red Cross Hospital; K. Hayasaki, Saiseikai
Kumamoto Hospital; H. Abe, Hokko Cardiovascular Hospital; K. Kadowaki,
Akita Medical Center; H. Murayama, Matsudo City Hospital; T. Joh, Ehime
Prefectural Central Hospital; K. Kanmatsuse, Nihon University Surugadai
Hospital; T. Katagiri, Showa University School of Medicine; S. Watanabe, Gifu
Prefectural Hospital; K. Dohi, Nara Medical University; K. Kodama, Osaka
Police Hospital; K. Tateda, Asahikawa City Hospital; M. Murata, Mito Saisei-
Kai General Hospital; N. Hayashida, St. Luke International Hospital; Y. Yabe,
School of Medicine, Toho University; M. Arita, Yokohama Minami Kyosai
Hospital; K. Sakai, Tousei General Hospital; T. Kita, Cardiovascular Center,
Sakakibara Hospital; H. Toda, Kagoshima Municipal Hospital; T. Meguro,
Sendai Shakaihoken Hospital; M. Harada, Harada Heart Institute; N. Higuma,
Niigata City General Hospital; T. Nagai, Nagaoka Red Cross Hospital; A.
Takizawa, Shizuoka City Hospital; H. Hirayama, Nagoya Daini Red Cross
Hospital; E. Murakami, Kanazawa University School of Medicine; K. Hirose,
Ohtsu Red Cross Hospital; S. Ishise, Maizuru Kyosai Hospital; K. Shimomura,
National Cardiovascular Center; M. Inada, Kansai Medical University; M.
Chino, Ashikaga Red Cross Hospital; K. Hiramori, Iwate Medical University
School of Medicine; K. Yokoyama, Yamagata Prefectural Central Hospital; T.
Munakata, Sendai City Medical Center, Sendai Open Hospital; S. Takase,
Saiseikai Maebashi Hospital; S. Saito, Nihon University Itabashi Hospital; Y.
Dohi, Saitama Medical School; H. Nakamura, School of Medicine, National
Defense Medical College; H. Nishimura, Kameda General Hospital; T. Taka-
hashi, Komoro Kosei Hospital; H. Kanaya, Ishikawa Prefectural Hospital; M.
Takahashi, Rakuyou Hospital; T. Minamino, Sakurabashi Watanabe Hospital;
M. Yokoyama, Kobe University School of Medicine; T. Iwasaki, Hyogo College
of Medicine; K. Mitsuto, Kurashiki Central Hospital; Y. Hayashi, Akanekai
Tsuchiya General Hospital; T. Okuhara, Asa Municipal Hospital; M. Matsuzaki,
Yamaguchi University School of Medicine; T. Yorozu, Yamaguchi Saiseikai
General Hospital; H. Toshima, Kurume University School of Medicine; K.
Ishikawa, Kyorin University School of Medicine; H. Ogawa, Tokuyama Chuoh
Hospital; T. Syougase, Nikko Memorial Hospital; Y. Miyazawa, Cardiovascular
Center of Sendai; H. Takeda, Semine Prefectural Hospital; A. Sibata, Niigata
University School of Medicine; H. Yamaguchi, Juntendo University School of
Medicine; S. Takahashi, Kosei General Hospital; M. Saito, Jichi Medical School,
Omiya Medical Center; M. Nomura, Fujita Health University School of Medi-
cine; J. Tsunekawa, Okazaki Municipal Hospital; H. Nishikawa, Yamada Red
Cross Hospital; A. Wakabayashi, Kitano Hospital; J. Yoshikawa, Kobe General
Hospital; K. Shoji, Okayama Red Cross Hospital; T. Sawayama, Kawasaki
Medical School; E. Hyakuna, Shimonoseki Saikeikai General Hospital; H.
Takeda, Kagawa Prefectural Central Hospital; Y. Kikuchi, Kyusyu Kose-Inenkin
Hospital; T. Doi, Fukuoka Saiseikai General Hospital; S. Yano, Almeida
Hospital; and H. Tanaka, Faculty of Medicine, Kagoshima University.
Principal Investigator: C. Kawai. Steering Committee: C. Kawai (Chairman),
Y. Yui, S. Hosoda, M. Nobuyoshi, S. Suzuki, H. Sato, F. Takatsu, T. Motomiya,
K. Kanmatsuse, K. Kodama, Y. Yabe, T. Minamino, and S. Kimata. Controller:
M. Nakashima.
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